Category: Edwards LifesciencesSyndicate content

TAVI: Medtronic vows to appeal CoreValve ban in patent loss to Edwards Lifesciences

April 14, 2014 by Arezu Sarvestani

Medtech titan Medtronic plans to seek immediate appeal of a preliminary court injunction banning sales of its CoreValve transcatheter aortic valve implantation system.

TAVI: Medtronic has 7 days to appeal CoreValve ban in patent loss to Edwards Lifesciences

TAVI: Court limits U.S. sales of Medtronic's CoreValve

April 11, 2014 by Arezu Sarvestani

Edwards Lifesciences lands a preliminary injunction limiting Medtronic from selling its CoreValve transcatheter aortic valve implantation system in the U.S.

TAVI: Court bans U.S. sales of Medtronic's CoreValve

Edwards Lifesciences lands E.U. approval for INTUITY Elite aortic valve

April 4, 2014 by Arezu Sarvestani

California-based Edwards Lifesciences launches commercial efforts after winning European CE Mark approval for its next-generation INTUITY Elite surgical aortic valve.

Edwards Lifesciences lands Euro approval for INTUITY Elite aortic valve

Edwards Lifesciences (NYSE:EW) announced today that it won CE Mark approval in the European Union to market its next-generation INTUITY Elite aortic valve.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 by Arezu Sarvestani

More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.

fired/hired

The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014: Sapien XT bests CoreValve in small head-to-head study

March 31, 2014 by Brad Perriello

Edwards Lifesciences' Sapien XT replacement heart valve bests Medtronic's CoreValve in a small head-to-head study presented at the American College of Cardiology's annual conference.

ACC 2014: Sapien XT bests CoreValve in small head-to-head study

UPDATED March 31, 2014, with comment from Medtronic

Edwards Lifesciences announces 1st Fortis mitral valve implants

March 7, 2014 by Brad Perriello

Edwards Lifesciences says the 1st 3 patients worldwide were implanted with its Fortis transcatheter mitral valve implant.

Edwards Lifesciences announces 1st Fortis mitral valve implants

Edwards Lifesciences (NYSE:EW) said a surgical team at London's St. Thomas' Hospital implanted the 1st 3 patients with its Fortis transcatheter mitral valve implant.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp